PL417879A1 - Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 - Google Patents
Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2Info
- Publication number
- PL417879A1 PL417879A1 PL417879A PL41787914A PL417879A1 PL 417879 A1 PL417879 A1 PL 417879A1 PL 417879 A PL417879 A PL 417879A PL 41787914 A PL41787914 A PL 41787914A PL 417879 A1 PL417879 A1 PL 417879A1
- Authority
- PL
- Poland
- Prior art keywords
- derivative
- aminocephalosporanic acid
- applications
- biologic activity
- activity inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
Ujawniono zastosowanie pochodnej kwasu 7-aminocefalosporanowego - cefazoliny w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 i interleukiny 2. Przedmiotem zgłoszenia jest także preparat farmaceutyczny zawierający terapeutycznie skuteczną ilość cefazoliny jako substancję aktywną oraz farmaceutycznie dopuszczalne nośniki i/lub substancje pomocnicze, do stosowania w zapobieganiu lub leczeniu chorób takich jak łuszczyca, zapalenie jelit, sarkoidoza, białaczki T-komórkowe lub odrzucanie przeszczepów. Ponadto, preparat farmaceutyczny ma postać odpowiednią do podawania dożylnie lub domięśniowo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL40550613A PL405506A1 (pl) | 2013-09-30 | 2013-09-30 | Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 |
PCT/IB2014/001940 WO2015044762A1 (en) | 2013-09-30 | 2014-09-29 | 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity |
Publications (2)
Publication Number | Publication Date |
---|---|
PL417879A1 true PL417879A1 (pl) | 2017-02-13 |
PL235635B1 PL235635B1 (pl) | 2020-09-21 |
Family
ID=51903949
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL40550613A PL405506A1 (pl) | 2013-09-30 | 2013-09-30 | Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 |
PL14799527T PL3068491T3 (pl) | 2013-09-30 | 2014-09-29 | Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2 |
PL417879A PL235635B1 (pl) | 2013-09-30 | 2014-09-29 | Pochodna kwasu 7-aminocefalosporanowego-cefazolina oraz zawierający ją preparat farmaceutyczny do zastosowania w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 oraz interleukiny 2 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL40550613A PL405506A1 (pl) | 2013-09-30 | 2013-09-30 | Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 |
PL14799527T PL3068491T3 (pl) | 2013-09-30 | 2014-09-29 | Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160235762A1 (pl) |
EP (1) | EP3068491B1 (pl) |
AU (2) | AU2014326355B2 (pl) |
CA (1) | CA2925652A1 (pl) |
DK (1) | DK3068491T3 (pl) |
ES (1) | ES2747635T3 (pl) |
PL (3) | PL405506A1 (pl) |
PT (1) | PT3068491T (pl) |
WO (1) | WO2015044762A1 (pl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3124016T3 (da) | 2015-07-31 | 2019-12-09 | Univ Warszawski Medyczny | Antipsoriatisk emulsionspræparat omfattende cefazolin |
US11278505B2 (en) | 2017-04-24 | 2022-03-22 | University Of Massachusetts | Diagnosis and treatment of vitiligo |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891370A (en) | 1981-12-14 | 1990-01-02 | Merck & Co., Inc. | Cephalosporin derivatives as anti-inflammatory agents |
CN1247057A (zh) * | 1999-06-07 | 2000-03-15 | 李桂华 | 口腔保洁剂的配制方法 |
CA2490062A1 (en) * | 2002-05-23 | 2003-12-04 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
JP2007131535A (ja) * | 2003-12-26 | 2007-05-31 | Tokai Univ | 蛋白修飾物生成抑制剤 |
CU23472A1 (es) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
WO2007065167A1 (en) * | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
CU23716A1 (es) | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
-
2013
- 2013-09-30 PL PL40550613A patent/PL405506A1/pl unknown
-
2014
- 2014-09-29 ES ES14799527T patent/ES2747635T3/es active Active
- 2014-09-29 PL PL14799527T patent/PL3068491T3/pl unknown
- 2014-09-29 DK DK14799527.8T patent/DK3068491T3/da active
- 2014-09-29 EP EP14799527.8A patent/EP3068491B1/en active Active
- 2014-09-29 US US15/026,125 patent/US20160235762A1/en not_active Abandoned
- 2014-09-29 PL PL417879A patent/PL235635B1/pl unknown
- 2014-09-29 WO PCT/IB2014/001940 patent/WO2015044762A1/en active Application Filing
- 2014-09-29 CA CA2925652A patent/CA2925652A1/en active Pending
- 2014-09-29 AU AU2014326355A patent/AU2014326355B2/en active Active
- 2014-09-29 PT PT147995278T patent/PT3068491T/pt unknown
-
2017
- 2017-07-27 US US15/661,586 patent/US11452728B2/en active Active
-
2019
- 2019-09-26 AU AU2019236714A patent/AU2019236714B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014326355A1 (en) | 2016-04-28 |
DK3068491T3 (da) | 2019-10-14 |
WO2015044762A1 (en) | 2015-04-02 |
PT3068491T (pt) | 2019-10-24 |
AU2019236714A1 (en) | 2019-10-17 |
EP3068491A1 (en) | 2016-09-21 |
AU2019236714B2 (en) | 2020-10-15 |
US11452728B2 (en) | 2022-09-27 |
EP3068491B1 (en) | 2019-07-03 |
US20170319593A1 (en) | 2017-11-09 |
PL3068491T3 (pl) | 2019-12-31 |
PL235635B1 (pl) | 2020-09-21 |
AU2014326355B2 (en) | 2019-06-27 |
CA2925652A1 (en) | 2015-04-02 |
PL405506A1 (pl) | 2015-04-13 |
ES2747635T3 (es) | 2020-03-11 |
US20160235762A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
MX2022006258A (es) | Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina. | |
PH12016501790A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
PH12015502365B1 (en) | Bace1 inhibitors | |
PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
PL417879A1 (pl) | Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 | |
PH12017501668A1 (en) | Bace1 inhibitors | |
MX2018015707A (es) | Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta. | |
PL417876A1 (pl) | Zastosowania pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 i IL-2 | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
CO2018005367A2 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico | |
CL2016000222A1 (es) | Composiciones tópicas para el tratamiento de sudoración excesiva y métodos para utilizar las mismas | |
UA106471U (uk) | Засіб для лікування дерматологічних захворювань | |
IN2013MU02585A (pl) |